Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.
Audemard-Verger A, Le Gouge A, Pestre V, Courjon J, Langlois V, Vareil MO, Devaux M, Bienvenu B, Leroy V, Goulabchand R, Colombain L, Bigot A, Guimard T, Douadi Y, Urbanski G, Faucher JF, Maulin L, Lioger B, Talarmin JP, Groh M, Emmerich J, Deriaz S, Ferreira-Maldent N, Cook AR, Lengellé C, Bourgoin H, Mekinian A, Aouba A, Maillot F, Caille A. Audemard-Verger A, et al. Among authors: caille a. PLoS One. 2022 Aug 4;17(8):e0269065. doi: 10.1371/journal.pone.0269065. eCollection 2022. PLoS One. 2022. PMID: 35925914 Free PMC article. Clinical Trial.
Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial.
Leducq S, Samimi M, Bernier C, Soria A, Amsler E, Staumont-Sallé D, Gabison G, Chosidow O, Bénéton N, Bara C, Grange-Prunier A, Wierzbicka-Hainaut E, Brenaut E, Droitcourt C, Raison-Peyron N, Bourgoin H, Cornillier H, Machet L, Giraudeau B, Caille A, Maruani A. Leducq S, et al. Among authors: caille a. J Am Acad Dermatol. 2020 Jan;82(1):240-243. doi: 10.1016/j.jaad.2019.07.097. Epub 2019 Aug 5. J Am Acad Dermatol. 2020. PMID: 31394130 Clinical Trial. No abstract available.
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S, Caille A, Barbarot S, Bénéton N, Bessis D, Boccara O, Bursztejn AC, Chiaverini C, Dompmartin A, Droitcourt C, Gissot V, Goga D, Guibaud L, Herbreteau D, Le Touze A, Léauté-Labrèze C, Lorette G, Mallet S, Martin L, Mazereeuw-Hautier J, Phan A, Plantin P, Quéré I, Vabres P, Bourgoin H, Giraudeau B, Maruani A; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique. Leducq S, et al. Among authors: caille a. Trials. 2019 Dec 17;20(1):739. doi: 10.1186/s13063-019-3767-8. Trials. 2019. PMID: 31847908 Free PMC article.
Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
Marchand A, Caille A, Gissot V, Giraudeau B, Lengelle C, Bourgoin H, Largeau B, Leducq S, Maruani A. Marchand A, et al. Among authors: caille a. Trials. 2022 Jul 8;23(1):557. doi: 10.1186/s13063-022-06365-y. Trials. 2022. PMID: 35804404 Free PMC article.
Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial.
Bejan-Angoulvant T, Naccache JM, Caille A, Borie R, Nunes H, Ferreira M, Cadranel J, Crestani B, Cottin V, Marchand-Adam S; OrphaLung. Bejan-Angoulvant T, et al. Among authors: caille a. Respir Med Res. 2020 Nov;78:100770. doi: 10.1016/j.resmer.2020.100770. Epub 2020 May 23. Respir Med Res. 2020. PMID: 32777737 Clinical Trial.
Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.
Ferreira M, Bejan-Angoulvant T, Marchand-Adam S, Mousset E, Mureau E, Jouneau S, Nunes H, Montani D, Chenivesse C, Cadranel J, Bonniaud P, Crestani B, Cottin V, Caille A; OrphaLung.. Ferreira M, et al. Among authors: caille a. Respir Med Res. 2024 Nov 28;87:101144. doi: 10.1016/j.resmer.2024.101144. Online ahead of print. Respir Med Res. 2024. PMID: 39693827
188 results